1. Home
  2. CHMG vs AKBA Comparison

CHMG vs AKBA Comparison

Compare CHMG & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chemung Financial Corp

CHMG

Chemung Financial Corp

N/A

Current Price

$84.46

Market Cap

398.6M

Sector

Finance

ML Signal

N/A

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.91

Market Cap

343.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHMG
AKBA
Founded
1833
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
398.6M
343.4M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
CHMG
AKBA
Price
$84.46
$0.91
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$57.00
$4.67
AVG Volume (30 Days)
36.9K
8.7M
Earning Date
04-17-2026
05-07-2026
Dividend Yield
2.04%
N/A
EPS Growth
N/A
93.94
EPS
3.73
N/A
Revenue
N/A
N/A
Revenue This Year
$37.32
N/A
Revenue Next Year
$9.13
N/A
P/E Ratio
$22.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$49.82
$0.81
52 Week High
$86.00
$3.19

Technical Indicators

Market Signals
Indicator
CHMG
AKBA
Relative Strength Index (RSI) 62.64 41.57
Support Level $80.16 $0.84
Resistance Level N/A $0.96
Average True Range (ATR) 1.83 0.07
MACD 0.10 0.01
Stochastic Oscillator 87.64 24.74

Price Performance

Historical Comparison
CHMG
AKBA

About CHMG Chemung Financial Corp

Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: